Article Text

Download PDFPDF
Association of accelerometer-measured physical activity and its change with progression to chronic kidney disease in adults with type 2 diabetes and overweight/obesity
  1. Mengyi Liu1,2,3,4,5,
  2. Yanjun Zhang1,2,3,4,5,
  3. Yuanyuan Zhang1,2,3,4,5,
  4. Panpan He1,2,3,4,5,
  5. Chun Zhou1,2,3,4,5,
  6. Ziliang Ye1,2,3,4,5,
  7. Sisi Yang1,2,3,4,5,
  8. Xiaoqin Gan1,2,3,4,5,
  9. Fan Fan Hou1,2,3,4,5,
  10. Xianhui Qin1,2,3,4,5
  1. 1 Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China
  2. 2 National Clinical Research Center for Kidney Disease, Guangzhou, China
  3. 3 State Key Laboratory of Organ Failure Research, Guangzhou, China
  4. 4 Guangdong Provincial Institute of Nephrology, Guangzhou, China
  5. 5 Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, China
  1. Correspondence to Dr Xianhui Qin, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China; pharmaqin{at}126.com; Professor Fan Fan Hou, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China; ffhouguangzhou{at}163.com

Abstract

Objective To examine the long-term association of objectively measured moderate-to-vigorous physical activity (MVPA) and its longitudinal changes with progression to chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) and overweight/obesity.

Methods This study included 1746 participants in the Look AHEAD trial with baseline estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2. MVPA was measured at baseline, year 1, year 4 and year 8 using an RT3 accelerometer. The outcome was progression to CKD, defined as eGFR<60 mL/min per 1.73 m2 with a drop of ≥30% or end-stage kidney disease. Cox hazards models were fitted to examine the association between MVPA and outcomes.

Results Over a median follow-up of 12.0 years, 567 participants experienced progression to CKD. Overall, there was a linear inverse association of cumulative average total MVPA (per 100 min/week higher amount, HR: 0.91; 95% CI: 0.86 to 0.96) and MVPA accumulated in bouts of ≥10 min (per 100 minutes/week higher amount, HR: 0.81; 95% CI: 0.72 to 0.91) with progression to CKD. Moreover, an increase in total MVPA from baseline to year 4 (the fourth quartile, ≥63.2 min/week) was associated with a 33% lower risk of progression to CKD compared with the largest MVPA reduction (the first quartile, <−198.3 min/week). A lower risk of progression to CKD was also observed for increases in MVPA accumulated in bouts of both <10 min and ≥10 min.

Conclusions Longer MVPA time and increases in MVPA was associated with a reduced risk of progression to CKD in adults with overweight/obesity and T2D.

  • Physical activity
  • Accelerometer

Data availability statement

Data may be obtained from a third party and are not publicly available. The data sets analysed in the current study are available on application at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data may be obtained from a third party and are not publicly available. The data sets analysed in the current study are available on application at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository.

View Full Text

Footnotes

  • Contributors ML, FFH and XQ designed and conducted the research. ML and YanjunZhang performed the data management and statistical analyses. ML and XQ wrote the manuscript. All authors reviewed/edited the manuscript for important intellectual content. All authors read and approved the final manuscript. XQ is the guarantor of the project and accepts full responsibility for the work and/or the conduct of the study, had access to the data and controlled the decision to publish.

  • Funding The study was supported by the National Key Research and Development Program (2022YFC2009600, 2022YFC2009605 to XQ); the National Natural Science Foundation of China (81973133 to XQ); the National Natural Science Foundation of China (Key Program) (82030022 to FFH); the Program of Introducing Talents of Discipline to Universities, 111 Plan (D18005 to FFH); Guangdong Provincial Clinical Research Center for Kidney Disease (2020B1111170013 to FFH); Key Technologies R&D Program of Guangdong Province (2023B1111030004 to FFH).

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.